At a glance
ClinicalIndex Comparison RecordPhase 4Completed
Drug / intervention
valsartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure
In Brief
A Phase 4 clinical trial evaluating valsartan for Diastolic Dysfunction, Symptomatic Heart Failure. Completed, across 2 sites in 2 countries.
Detailed Summary
This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Switzerland
Collaborators--
Timeline
Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2002
First PostedSep 2005
Primary CompletionAug 2007
Study CompletionFeb 2008
TodayJul 2026
First PostedSep 15, 2005
Enrollment StartDec 1, 2002
Primary CompletionAug 1, 2007
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 20.8 years ago
Interventions
valsartandrug